Clinical Trials on Bacterial Infections in Finland

Total 1541 results

Turku University Hospital
Helsinki University Central Hospital; Satakunta Central Hospital; Päijät-Häme...

Recruiting

FMT in Initial CDI (FinCDI)

Clostridioides Difficile Infection

Finland
Helsinki University Central Hospital

Completed

Association of Cephalosporin Resistance and Surgical Site Infections in Patients Undergoing Pancreaticoduodenectomy

Surgical Site Infection | Pancreaticoduodenectomy | Biliary Tract Infection Bacterial

Finland
Arto Palmu
GlaxoSmithKline

Completed

Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage (FinIPcarr)

Pneumococcal Infections

Finland
The Miriam Hospital

Unknown

Gut Microbiota Changes After Fecal Microbiota Transplantation

Clostridium Difficile Infection

United States
Aeras
Statens Serum Institut

Completed

A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults

Tuberculosis

Finland
Helsinki University Central Hospital

Unknown

Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines (Ty21a-ASC)

Healthy

Finland
Finnish Institute for Health and Welfare
Turku University Hospital; GlaxoSmithKline

Completed

Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10

Pneumococcal Infections

Finland
Pfizer

Completed

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

MENINGOCOCCAL INFECTION

Finland, Poland
Arto Palmu
GlaxoSmithKline

Completed

Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage

Nasopharyngeal Carriage of Streptococcus Pneumoniae

Finland
Helsinki University Central Hospital

Completed

Targeting of Immune Response After Pneumococcal Vaccination (PncHR)

Pneumococcal Pneumonia

Finland
GlaxoSmithKline

Completed

Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease (FinIP)

Streptococcus Pneumoniae | Infections, Streptococcal

Finland
Turku University Hospital

Completed

Study of Lyme Neuroborreliosis

Lyme Neuroborreliosis

Finland
Helsinki University Central Hospital
University of Helsinki

Recruiting

Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines

Cholera | Typhoid Fever | Vaccine-Preventable Diseases

Finland
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.

Tetanus | Diphtheria | Acellular Pertussis

Finland
Kent Hospital, Rhode Island
National Institute of General Medical Sciences (NIGMS)

Active, not recruiting

Improving Rhode Island's Tuberculosis Preventive Services in Primary Care

Latent Tuberculosis

United States
Butler Hospital

Completed

Preventing Bacterial and Viral Infections Among Injection Drug Users

HIV | Bacterial Infection

United States
Northwell Health
Staten Island University Hospital

Completed

Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis (TB) in Elderly Residents of Nursing Homes?

Tuberculosis

United States
University of Turku
GlaxoSmithKline; Sanofi Pasteur, a Sanofi Company

Completed

EUpertstrain 4 Study of Bordetella Pertussis Isolates

Bordetella Pertussis, Whooping Cough

Finland
Tampere University

Completed

Helicobacter Pylori and Acute Alcohol Induced Pancreatitis

Helicobacter Infections | Pancreatitis, Acute

Finland
Brahms AG

Terminated

Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection

Sepsis | Infection | Bacterial Infection

United States
Koite Health Oy
University of Helsinki; Tampere University; Tampere University Hospital; Wellbeing...

Recruiting

Dual-light Antibacterial Photodynamic Therapy as an Adjunctive Treatment to Corticosteroid Treatment in OLP (RELIEF-OLP)

Oral Bacterial Infection | Dental Plaque | Oral Lichen Planus

Finland
Novartis Vaccines
Novartis

Completed

Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.

Meningococcal Meningitis

Finland, Poland
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population

Infections, Streptococcal

Belgium, Sweden, Finland
University of Helsinki

Completed

Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia (FINLEVO)

Sepsis | Bacteremia | Staphylococcus Aureus | Endocarditis

Finland
Northwell Health

Completed

Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?

HIV Infections | Latent Tuberculosis

United States
Microbiome Health Research Institute
Brown University; Tufts Medical Center; Indiana University; Edward Hospital

Terminated

Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection (STOOL)

Clostridium Difficile

United States
Helsinki University Central Hospital
Repolar Ltd.

Completed

Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis

Onychomycosis

Finland
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Finland
Pfizer

Completed

The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

Infections, Meningococcal

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children

Meningococcal Infections

Finland
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Finland
Finnish Institute for Health and Welfare
Merck Sharp & Dohme LLC; Wyeth-Lederle Vaccines; Pasteur Merieux Connaught

Completed

Efficacy Trial of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Vaccine Serotypes

Pneumococcal Infections | Otitis Media

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland
GlaxoSmithKline

Completed

Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612

Infections, Meningococcal

Finland
Quidel Corporation

Completed

Sofia 2 Lyme FIA Whole Blood Clinical Study

Borrelia; Infection, Burgdorferi (Erythema Chronicum Migrans)

United States
Oulu University Hospital
University of Oulu; Finnish Defense Forces; The Central Hospital of Kajaani; Huslab...

Unknown

Acute Upper Respiratory Tract Infection - When is Bacteria Involved?

Acute Upper Respiratory Tract Infection and Acute Bacterial Rhinosinusitis

Finland
GlaxoSmithKline

Completed

Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children

Infections, Meningococcal

Finland
University of Oxford
University of Turku; National Institute for Public Health and the Environment...

Completed

A Study Exploring Whooping Cough Protection in Children and Adults (BERT)

Pertussis

United Kingdom, Finland, Netherlands
GlaxoSmithKline

Completed

Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612

Infections, Meningococcal

Finland
Pfizer

Completed

Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children

Infections, Meningococcal

Finland
Impatients N.V. trading as myTomorrows
Inmunotek S.L.

No longer available

Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)

Urinary Tract Infections | Bladder Infection | Recurrent Urinary Tract Infection | Urinary Tract Infection Bacterial | Chronic Urinary Tract Infection

Czechia, Denmark, Serbia, France, Germany, Turkey, Belgium, Finland, Luxembourg, Netherlands, Norway, Romania, Slovakia, Slovenia, Sweden
Sanofi Pasteur, a Sanofi Company

Completed

Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

Virus Diseases | Bacterial Infections | Neisseria Meningitidis

Finland
GlaxoSmithKline

Completed

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

Infections, Meningococcal

Finland, Poland
National Institute of Allergy and Infectious Diseases...

Completed

The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients

HIV Infections | Mycobacterium Avium-intracellulare Infection

United States
Novartis Vaccines

Completed

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

Meningococcal Disease

Finland, Czech Republic
Pfizer

Completed

Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose

Meningococcal Infection

United States, Finland, Czechia, Sweden, Denmark, Germany
Colleen Kelly

Unknown

Fecal Transplant for Relapsing C. Difficile Infection

Clostridium Difficile

United States
GlaxoSmithKline

Completed

Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A

Streptococcus Pneumoniae | Infections, Streptococcal

Finland
Seres Therapeutics, Inc.
Syneos Health

Completed

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) (ECOSPOR)

Clostridium Difficile

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

Pneumococcal Infection

United States, Puerto Rico

Clinical Trials on Bacterial Infections in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations